Posts Tagged ‘low-risk prostate cancer’

NEW PROSTATE CANCER INFOLINK:  Men with low-risk prostate cancer who choose surgery need to realise the possible after-effects – reduced urinary and erectile function, shorter penis, penis distortion – they might have to live with for up to 35 years afterwards. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: NZ politicians currently trying to decide what to do about prostate cancer screening (the Health Selection Committee inquiry) should read the latest analysis of the big randomised European study into PSA testing.

It suggests population-based screening is not supportable. READ MORE> and HERE>

Mike Scott at this website notes:

…it is certainly a fair question for every man of 55-74 years of age and a PSA of less than 4.0 ng/ml whether he wants to have treatment for prostate cancer based on a 553 to 1 chance that treatment will actually affect his long-term survival, and given the well-known side effects of treatment.

We do believe that these data add emphasis to the value of expectant management as a method of caring for men with low-risk prostate cancer.

Read Full Post »

WEB MED: More than 75% of men diagnosed with low-risk prostate cancer undergo aggressive treatment — either complete removal of the prostate or radiation therapy, according to a new study.

That’s true, the researchers found, even in men with a low level of prostate-specific antigen (PSA) of under 4 nanograms per milliliter, one of the factors taken into account when treatment decisions are made. READ MORE>

Read Full Post »

URO TODAY: Watchful waiting may not be a wise choice for younger men diagnosed with low risk prostate cancer, a new study suggests.

Our pathologic findings and risk of biochemical recurrence after open radical prostatectomy question the wisdom of active surveillance in men with low-risk disease who have “long” life expectancies. READ MORE>

Read Full Post »

URO TODAY: You’re a “low risk” prostate cancer patient – what treatment do you choose?

A panel of three doctors – expert in active surveillance, surgery and radio therapy – look at a 62-year-old with Gleason 6, 2/12 positive biopsy samples, small volume, PSA 0.09 and good sexual function. READ MORE>

Read Full Post »

URO TODAY: Active surveillance protocols can be valuable when prostate cancer is managed well and treatment is recommended appropriately, according to two recent studies. READ MORE>

Read Full Post »

URO TODAY: Men with low-risk prostate cancer who are candidates for active surveillance often choose definitive therapy due to anxiety over their untreated cancer. READ MORE>

Read Full Post »

Older Posts »